Reneo Pharmaceuticals, Inc. RPHM
We take great care to ensure that the data presented and summarized in this overview for Reneo Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RPHM
View all-
Nea Management Company, LLC Timonium, MD4.79MShares$8.04 Million0.62% of portfolio
-
Bml Capital Management, LLC Zionsville, IN3.46MShares$5.81 Million3.46% of portfolio
-
Highbridge Capital Management LLC New York, NY3.06MShares$5.15 Million1.56% of portfolio
-
Tang Capital Management LLC San Diego, CA2.95MShares$4.95 Million0.43% of portfolio
-
Carlyle Group Inc. Washington, DC2.7MShares$4.53 Million0.69% of portfolio
-
River Vest Venture Management LLC St. Louis, MO2.53MShares$4.26 Million63.0% of portfolio
-
Octagon Capital Advisors LP New York, NY2.25MShares$3.78 Million0.92% of portfolio
-
Abingworth LLP London, X02.07MShares$3.48 Million1.6% of portfolio
-
Ikarian Capital, LLC Dallas, TX1.03MShares$1.72 Million0.3% of portfolio
-
Aisling Capital Management LP New York, NY886KShares$1.49 Million0.62% of portfolio
Latest Institutional Activity in RPHM
Top Purchases
Top Sells
About RPHM
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Insider Transactions at RPHM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 07
2024
|
Braden Michael Leonard |
BUY
Other acquisition or disposition
|
Direct |
102,076
+50.0%
|
-
|
|
Oct 07
2024
|
Braden Michael Leonard |
BUY
Other acquisition or disposition
|
Indirect |
345,739
+50.0%
|
-
|
|
Oct 04
2024
|
Nicholas A Saccomano President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,556
+50.0%
|
-
|
|
Oct 04
2024
|
Jason A. Leverone Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,331
+50.0%
|
-
|
|
Oct 04
2024
|
R Michael Carruthers |
BUY
Grant, award, or other acquisition
|
Direct |
4,939
+47.57%
|
-
|
|
Sep 25
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
68,746
+1.95%
|
$68,746
$1.5 P/Share
|
|
Sep 24
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
29,600
+0.87%
|
$29,600
$1.41 P/Share
|
|
Sep 18
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
806
+0.02%
|
$806
$1.4 P/Share
|
|
Sep 17
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
55,300
+1.62%
|
$55,300
$1.36 P/Share
|
|
Sep 16
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
172,747
+4.97%
|
$172,747
$1.37 P/Share
|
|
Sep 13
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
150,000
+4.57%
|
$150,000
$1.31 P/Share
|
|
Sep 12
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
36,176
+1.2%
|
$36,176
$1.4 P/Share
|
|
Aug 14
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
100,487
+3.3%
|
$100,487
$1.41 P/Share
|
|
Aug 13
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
171,339
+5.68%
|
$171,339
$1.39 P/Share
|
|
May 14
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
414,281
+7.21%
|
$414,281
$1.55 P/Share
|
|
Aug 28
2023
|
Ashley Hall Chief Development Officer |
SELL
Open market or private sale
|
Direct |
15,625
-28.29%
|
$93,750
$6.28 P/Share
|
|
Aug 28
2023
|
Ashley Hall Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+22.05%
|
$15,625
$1.8 P/Share
|
|
Jul 26
2023
|
Michael G Grey |
SELL
Bona fide gift
|
Direct |
50,000
-100.0%
|
-
|
|
Jun 23
2023
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
100,000
-2.92%
|
$700,000
$7.1 P/Share
|
|
May 08
2023
|
Niall O'Donnell Director |
BUY
Open market or private purchase
|
Indirect |
125,000
+5.4%
|
$1,000,000
$8.0 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 25.8K shares |
|---|---|
| Other acquisition or disposition | 448K shares |
| Open market or private purchase | 1.2M shares |